Tezepelumab and dupilumab effective at reducing asthma exacerbations in patients with eosinophilia

Ontario: New trial from Ontario revealed that biologics like Tezepelumab and dupiliumab can successfully reduce exacerbations in asthma patients by improving lung function. The trial results were published in the journal Annals of Allergy, Asthma & Immunology. 

Asthma is a respiratory condition that is associated with significant morbidity. Asthma that is inadequately controlled by high-dose inhaled corticosteroids and long-acting β2-agonists or oral corticosteroids may have an advantage from using biologics. Though there is data on the use of biologics for asthma, no trial has directly compared biologics to manage uncontrolled asthma. Hence Tyler Pitre et al from Ontario, Canada have conducted a trial to compare the relative efficacy of biologics in asthma. 

Randomized trials that addressed biologic therapies were included from inception to May 31, 2022. The researchers independently screened references, extracted data, and assessed the risk of bias. A frequentist network meta-analysis was performed, and certainty of evidence was assessed using the GRADE approach. Dichotomous outcomes were presented as absolute risk differences per 1000 patients and relative risk (RR) with 95% confidence intervals (95% CI) and continuous outcomes were presented as mean difference (MD) and 95% CI.